FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

Tardive Dyskinesia

Austedo (deutetrabenazine) (by Teva Pharmaceuticals), Initial approval April 2017
For the treatment of chorea associated with Huntington’s disease and tardive dyskinesia

Ingrezza (valbenazine) (by Neurocrine Biosciences), Approved April 2017
For the treatment of tardive dyskinesia

T-Cell Lymphoma

Beleodaq (belinostat) (by Spectrum Pharmaceuticals), Approved July 2014
For the treatment of relapsed or refractory peripheral T-cell lymphoma

Folotyn (pralatrexate injection) (by Allos Therapeutics), Approved September 2009
For the treatment of peripheral T-cell lymphoma

Thrombocytopenia and Thrombocytopenia Prevention

Argatroban Injection (by Texas Biotechnology Corporation, SmithKline Beecham), Approved June 2000
Anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia.

Elelyso (taliglucerase alfa) (by Pfizer), Approved May 2012
For the treatment of Gaucher disease

Soliris (eculizumab) (by Alexion), Approved March 2007
For the treatment of paroxysmal nocturnal hemoglobinuria

Soliris (eculizumab) (by Alexion), Approved September 2011
For the treatment of atypical hemolytic uremic syndrome

Thromboembolism

Adempas (riociguat) (by Bayer Healthcare Pharmaceuticals), Approved October 2013
For the treatment of Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension

Eliquis (apixaban) (by Bristol-Myers Squibb), Approved December 2012
For the prevention of stroke and systemic embolism resulting from nonvalvular atrial fibrillation

Thrombosis

Argatroban Injection (by Texas Biotechnology Corporation, SmithKline Beecham), Approved June 2000
Anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia.

Arixtra (by Organon, Sanofi-Synthelabo), Approved December 2001
Injectable solution for the prevention of deep vein thrombosis

Brilinta (ticagrelor) (by AstraZeneca), Approved July 2011
For the reduction of thrombotic events in patients with acute coronary syndrome

Innohep (tinzaparin sodium) injectable (by DuPont Merck Pharmaceutical Company), Approved July 2000
For the treatment of acute symptomatic deep vein thrombosis

Kengreal (cangrelor) (by The Medicines Company), Approved June 2015
For reducing periprocedural thrombotic events

Lovenox (enoxaparin sodium) Injection (by Rhone Poulenc Rorer), Approved May 1997
Treatment for deep vein thrombosis

Normiflo (by Wyeth), Approved May 1997
Treatment for deep venous thrombosis

Xarelto (rivaroxaban) (by Bayer), Approved July 2011
For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery

Zontivity (vorapaxar) (by Merck), Approved May 2014
For the reduction of thrombotic cardiovascular events

Thyroid Cancer

Cometriq (cabozantinib) (by Exelixis), Approved November 2012
For the treatment of metastatic medullary thyroid cancer

Lenvima (lenvatinib) (by Eisai), Approved February 2015
For the treatment of thyroid cancer

Vandetanib (vandetanib) (by AstraZeneca), Approved April 2011
For the treatment of thyroid cancer

Thyroid Disease

Levoxyl (by Jones Pharma), Approved May 2001
Oral therapy for the treatment of hypothyroidism and suppression of thyroid-stimulating hormone (TSH)

Thyroid Disorders

Levo-T (levothyroxine sodium) (by Mova Pharmaceutical), Approved March 2002
Indicated for the treatment of hypothyroidism and the suppression of thyroid stimulating hormone

Levoxyl (by Jones Pharma), Approved May 2001
Oral therapy for the treatment of hypothyroidism and suppression of thyroid-stimulating hormone (TSH)

Natpara (parathyroid hormone) (by NPS Pharmaceuticals), Approved January 2015
For the control hypocalcemia in patients with hypoparathyroidism

Parsabiv (etelcalcetide) (by Amgen), Approved February 2017
For the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis

Sensipar (cinacalcet) (by Amgen), Approved March 2004
For the treatment of secondary hyperparathyroidism and hypercalcemia in parathyroid carcinoma patients

Synthroid (levothyroxine sodium) (by Abbott Laboratories), Approved July 2002
For replacement or supplemental therapy for hypothyroidism and pituitary thyroid stimulating hormone suppression

Tinea Capitis (Ringworm of the Scalp)

Mentax (1% butenafine HCl cream) (by Penederm), Approved January 1997
Treatment for tinea corporis (ringworm) and tinea cruris (groin fungus)

Toenail Fungus (Onychomycosis)

Jublia (efinaconazole) 10% topical gel (by Valeant Pharmaceuticals), Approved June 2014
For the treatment of onychomycosis of the toenails

Kerydin (tavaborole) (by Anacor), Approved July 2014
For the treatment of onychomycosis of the toenails

Transplant Rejection

CellCept (by Roche), Approved February 1998
Treatment for the prevention of organ rejection inpatients undergoing heart transplants

Envarsus XR (tacrolimus extended-release) (by Veloxis), Approved July 2015
For the prophylaxis of organ rejection in kidney transplant patients

Prograf (by Fujisawa Healthcare), Approved April 1997
Treatment for the prevention of kidney transplant rejection

Rapamune (sirolimus) oral solution (by Wyeth), Approved September 1999
Oral solution of sirolimus

Rapamune (sirolimus) Tablets (by Wyeth), Approved August 2000
For treatment of kidney rejection

Simulect (by Novartis), Approved May 1998
Treatment for acute organ transplant rejection

Zenapax (by Roche), Approved December 1997
Treatment to prevent rejection of kidney transplants

Zortress (everolimus) (by Novartis), Approved May 2010
For the prevention of organ rejection following kidney transplant

Turner Syndrome

Saizen (by Ares-Serono), Approved May 1996
Treatment for growth hormone deficiency and Turner Syndrome